Agentix Biopharma

Agentix Biopharma is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that modulate the endocannabinoid system to treat metabolic and inflammatory diseases. The company's lead candidate, AGTX-2001, is a peripherally restricted, dual CB1/CB2 receptor agonist designed to treat conditions such as type 2 diabetes, obesity, and fatty liver disease without crossing the blood-brain barrier. By targeting peripheral cannabinoid receptors, Agentix aims to improve metabolic health while avoiding the central nervous system side effects typically associated with first-generation cannabinoid modulators. The company leverages intellectual property licensed from the National Institutes of Health (NIH) to advance its pipeline of small molecule candidates.